Targeting HRD in Ovarian Cancer with PARP Inhibitors: Oral Olaparib Is Well Tolerated in Combination With Carboplatin in BRCA-Deficient Disease
Credit: Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute.
This lecture was presented ...
read more ↘
This lecture was presented ...
read more ↘
Login to view comments.
Click here to Login
